Assessing the clinical benefit of NMP22 in the surveillance of patients with non–muscle-invasive bladder cancer and negative cytology: a decision-curve analysis

BACKGROUND: Several studies have shown that abnormal levels of nuclear matrix protein 22 (NMP22) are associated with bladder cancer, leading to NMP22 being approved as a urinary biomarker by the FDA. Nonetheless, the clinical significance of NMP22 remains unclear. OBJECTIVE: To use decision analysis...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Shariat, Shahrokh F., Savage, Caroline, Chromecki, Thomas F., Sun, Maxine, Scherr, Douglas S., Lee, Richard K., Lughezzani, Giovanni, Remzi, Mesut, Marberger, Michael J., Karakiewicz, Pierre I., Vickers, Andrew J.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3334293/
https://ncbi.nlm.nih.gov/pubmed/21692050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25903
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires